日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study

膀胱内注射Disitamab Vedotin (RC48)治疗HER2表达高危非肌层浸润性膀胱癌:一项单臂、剂量递增的I期临床试验研究

Chen, Xu; Huang, Ming; Chen, Zehua; Zhang, Chengjunyu; Pan, Bolin; Liu, Chu; Xu, Wentong; Fang, Jianmin; Huang, Jiang; Lin, Tianxin

A Novel Flow Cytometry Array for High Throughput Detection of SARS-CoV-2 Antibodies

一种用于高通量检测SARS-CoV-2抗体的新型流式细胞仪阵列

Zhang, Benyue; Zhang, Zhuo; Zhao, Yichao; Lu, Jingqiao; Fang, Jianmin; Petritis, Brianne; Whittaker, Kelly; Huang, Rani; Huang, Ruo-Pan

Combination detection of IgG- and IgA-related autoantibodies for the early diagnosis of gastric cancer

联合检测IgG和IgA相关自身抗体用于胃癌早期诊断

Fu, Congcong; Wang, Tao; Zhou, Xianzhu; Fang, Jianmin; Wang, Yanlin; Wang, Yuxin; Yin, Xiaomao; Zhu, Wei; Dong, Hua; Du, Yiqi; Luo, Shuhong; Huang, Ruo-Pan

Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform.

利用基于 2A 肽的 FaBody 平台解决 IgG 样双特异性抗体的轻链错配问题。

Li Dong, Zheng Pengfan, Yao Xuejing, Zhang Baopeng, Zhang Jiekun, Qu Yaocheng, Yun Shasha, Li Yanzhen, Chen Shanshan, Fang Jianmin

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Disitamab Vedotin治疗人表皮生长因子受体2阳性局部晚期或转移性尿路上皮癌患者的疗效和安全性:两项II期临床试验的联合分析

Sheng, Xinan; Wang, Lin; He, Zhisong; Shi, Yanxia; Luo, Hong; Han, Weiqing; Yao, Xin; Shi, Benkang; Liu, Jiyan; Hu, Changlu; Liu, Ziling; Guo, Hongqian; Yu, Guohua; Ji, Zhigang; Ying, Jianming; Ling, Yun; Yu, Shiying; Hu, Yi; Guo, Jianming; Fang, Jianmin; Zhou, Aiping; Guo, Jun

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

抗体药物偶联物联合疗法在实体瘤治疗中的前景与挑战

Wei, Qing; Li, Peijing; Yang, Teng; Zhu, Jiayu; Sun, Lu; Zhang, Ziwen; Wang, Lu; Tian, Xuefei; Chen, Jiahui; Hu, Can; Xue, Junli; Ma, Letao; Shimura, Takaya; Fang, Jianmin; Ying, Jieer; Guo, Peng; Cheng, Xiangdong

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study

Disitamab vedotin(一种靶向 HER2 的抗体药物偶联物)用于治疗 HER2 过表达和 HER2 低表达的晚期乳腺癌患者:一项 I/Ib 期研究

Wang, Jiayu; Liu, Yunjiang; Zhang, Qingyuan; Li, Wei; Feng, Jifeng; Wang, Xiaojia; Fang, Jianmin; Han, Yiqun; Xu, Binghe

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Telitacicept治疗活动性系统性红斑狼疮患者:一项2b期随机、双盲、安慰剂对照试验的结果

Wu, Di; Li, Jing; Xu, Dong; Merrill, Joan T; van Vollenhoven, Ronald F; Liu, Yi; Hu, Jiankang; Li, Yang; Li, Fen; Huang, Chenghui; Wang, Guochun; Li, Xiaomei; Zhao, Jianhong; Zhao, Dongbao; Huang, Cibo; Liu, Huaxiang; Wei, Wei; Shi, Guixiu; Lu, Fuai; Zuo, Xiaoxia; Bi, Liqi; Li, Zhijun; Wang, Xiaoxia; Zhang, Miaojia; Tie, Ning; Li, Juan; Mo, Hanyou; Fang, Jianmin; Bao, Chunde; Zhang, Fengchun

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial

Disitamab vedotin (RC48) 联合 toripalimab 治疗 HER2 表达的晚期胃癌或胃食管交界处癌及其他实体瘤:一项多中心、开放标签、剂量递增和扩展的 1 期试验

Wang, Yakun; Gong, Jifang; Wang, Airong; Wei, Jia; Peng, Zhi; Wang, Xicheng; Zhou, Jun; Qi, Changsong; Liu, Dan; Li, Jian; Lu, Ming; Lu, Zhihao; Cao, Yanshuo; Yuan, Jiajia; Zhang, Ruyan; Fang, Jianmin; Zhang, Xiaotian; Shen, Lin

Tannic acid protects against colitis by regulating the IL17 - NFκB and microbiota - methylation pathways

单宁酸通过调节 IL17 - NFκB 和微生物群甲基化途径预防结肠炎

Minghui Wang, Xiaoxuan Xu, Mingxuan Sheng, Ming Zhang, Fang Wu, Zhi Zhao, Meng Guo, Bing Fang, Jianmin Wu